Form 4: Apellis Pharmaceuticals Acquired by Biogen for $41/Share

Apellis Pharmaceuticals has been acquired by Biogen in a transaction valued at $41.00 per share plus a contingent value right.

Summary

• Apellis Pharmaceuticals, Inc. has completed its merger with a subsidiary of Biogen Inc.
• Shareholders received $41.00 per share in cash plus one non-transferable contingent value right (CVR) per share.
• The CVR entitles holders to potential additional payments of up to $4.00 per share upon the achievement of specific milestones.
• All outstanding equity awards, including RSUs and stock options, were converted into the right to receive the cash consideration and CVRs, subject to specific vesting and performance conditions.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive outcome for shareholders, as the acquisition provides a clear exit at a defined premium with additional upside potential via CVRs.

Positives

• Shareholders received a definitive cash exit price of $41.00 per share.
• The inclusion of a CVR provides potential upside of up to $4.00 per share if specific milestones are met.
• The transaction provides immediate liquidity for equity holders.

Negatives

• The company ceases to exist as an independent publicly traded entity.
• Future growth potential is now captured by the parent company, Biogen.

Risks

• The $4.00 per share CVR is contingent upon achieving specific milestones, which may not be met.
• The CVR is non-transferable, limiting liquidity for holders.
• Payments under the CVR are subject to tax withholding.

Future Outlook

The company has been acquired and is now a wholly owned subsidiary of Biogen; therefore, no independent future guidance is provided.

Management Comments

• The transaction was executed pursuant to the Agreement and Plan of Merger dated March 31, 2026.

Industry Context

StockSavvy.ai notes that this acquisition reflects the ongoing trend of large-cap biopharmaceutical companies acquiring mid-cap firms with specialized pipelines to bolster their therapeutic portfolios.

Comparison to Industry Standards

• The use of CVRs in biopharma M&A is a standard mechanism to bridge valuation gaps between buyers and sellers regarding clinical trial outcomes.
• The acquisition price reflects a premium typical for biotech takeovers in the current market environment.

Corporate Governance

Stakeholder Impact

• Shareholders receive cash for their holdings.
• Employees face integration into the parent company structure.
• Creditors are subject to the terms of the merger agreement.

Next Steps

• Achievement of milestones related to the CVR agreement.
• Integration of Apellis operations into Biogen.

Key Dates

Keywords

Apellis Pharmaceuticals, Biogen, Merger, Acquisition, APLS, Contingent Value Right, CVR